Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1466P - Gut microbiota mediates the protective effects of postbiotics attenuating the immune-related adverse events in non-small-cell lung cancer patients: A randomized, controlled trial in Chongqing, China

Date

21 Oct 2023

Session

Poster session 20

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Huiqing Yu

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

H. Yu1, M. Chen2

Author affiliations

  • 1 Department Of Geriatric Oncology And Department Of Palliative Care, Chongqing Cancer Hospital, 400000 - Chongqing/CN
  • 2 Clinical Nutrition, Chongqing Cancer Hospital, 400000 - Chongqing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1466P

Background

To evaluate the effects of JK5G postbiotics on regulating the imbalanced gut microbiota and its impacts on the efficacy and incidence rate of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).

Methods

We conducted a randomized, controlled trial in China and included non-squamous or squamous NSCLC patients without EGFR, ROS1, and ALK alteration, stage IIIb-IV. Patients were randomly (1:1) divided into two groups to receive four cycles of programmed cell death-1 (PD-1) plus chemotherapy plus placebo (control group) or to receive PD-1 plus chemotherapy plus JK5G postbiotics (JK5G group). The primary endpoint were adverse effects, quality of life (QoL), 16S DNA sequencing of gut microbiota, blood inflammatory cytokines, and lymphocyte subsets. This study was registered at www.chictr.org.cn (ChiCTR2200064690).

Results

60 patients were enrolled. The JK5G group had better QoL and nutritional levels, as well as lower depression symptoms than the control group (all p < 0.05). The JK5G group had a lower incidence of anemia (55.56% vs. 11.11%, p = 0.012), decreased lymphocyte count (33.33% vs. 0%, p = 0.019), decreased appetite (55.56% vs. 16.67%, p = 0.035), nausea (55.56% vs. 11.11%, p = 0.012), and asthenia (50.00% vs. 11.11%, p = 0.034) than the control group. Moreover, JK5G attenuated intestinal flora imbalance, accompanied by increased Faecalibacterium, Ruminococcaceae, and fecal butyrate concentration. Furthermore, JK5G administration significantly decreased the pro-inflammatory markers, including TNF-α, IL-2, and C-reactive protein (CRP) (p < 0.05). Significant increases in CD3+CD4+ T cells and CD4/CD8 ratio were observed in the peripheral blood of JK5G group patients (p < 0.05).

Conclusions

Our current findings indicated that JK5G postbiotics may attenuated irAEs, enhanced the QoL and nutrition levels in advanced NSCLC patients who received ICIs. JK5G postbiotics could improve the gut microbiota structures and accompanied with the ameliorate of tumor microenvironment and inflammation.

Clinical trial identification

ChiCTR2200064690.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.